Clinical trial / 2013
Phyllanthus emblica extract improved endothelial function, oxidative stress markers, lipid profile, and HbA1c in patients with type 2 diabetes.
Eighty patients with type 2 diabetes were randomized to receive P. emblica extract (250 mg or 500 mg twice daily), atorvastatin (10 mg daily), or placebo for 12 weeks. P. emblica at 250 mg, 500 mg, and atorvastatin significantly decreased the reflection index (-2.25%±1.37% to -9.13%±2.56%, -2.11%±0.98% to -10.04%±0.92%, and -2.68%±1.13% to -11.03%±3.93%, respectively), indicating improved endothelial function. Biomarkers of oxidative stress, systemic inflammation, lipid profile, and HbA1c levels also significantly improved compared with baseline and placebo. All treatments were reported as well tolerated without significant changes in laboratory safety parameters.
- Study type
- Randomized, double-blind, controlled trial
- Who was studied
- 80 patients with type 2 diabetes mellitus who completed the study
- What was measured
- Endothelial function via salbutamol challenge, oxidative stress biomarkers, hs-CRP, lipid profile, and HbA1c
THE PAPER
Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study.
Usharani P, Fatima N, Muralidhar N. Diabetes Metab Syndr Obes, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.